FAPI-mFS

• UNSPSC Description:

  FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu[1].

• Target Antigen:

  FAP; Radionuclide-Drug Conjugates (RDCs)

• Type:

  Peptides

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/fapi-mfs.html

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(N[C@H](C(N1CCN(CCCOC2=CC=C(N=CC=C3C(NCC(N4[C@H](C#N)CC(F)(F)C4)=O)=O)C3=C2)CC1)=O)CCCCNC(C5=CC(OS(F)(=O)=O)=CC=C5)=O)CN6CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC6

• Molecular Weight:

  1203.25

• References & Citations:

  [1]Cui XY, et al., Covalent targeted radioligands potentiate radionuclide therapy. Nature. 2024 Jun;630(8015):206-213.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  3023869-94-2